REVIEW

An update on molecular genetics of gastrointestinal stromal tumours

L Tornillo, L M Terracciano

J Clin Pathol 2006;59:557–563. doi: 10.1136/jcp.2005.031112

Gastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal tumours of the gastrointestinal tract. Most of them show activating mutations of the genes coding for KIT or platelet-derived growth factor receptor α (PDGFR α), two receptor tyrosine kinases (RTKs). The RTK inhibitor Imatinib (Gleevec[®], Novartis, Switzerland), induces regression of the tumour. The level of response to treatment, together with other clinicopathological parameters is related to the type and site of the activating mutation, thus suggesting that these tumours should be classified according to the molecular context. This is confirmed also by the phenomenon of the resistance to treatment, which arises because of different mechanisms (second mutation, amplification, activation of other RTKs) and can be fought only by specific RTK inhibitors, that are at present under development. RTK activation involves an homogeneous transduction pathway whose components (MAPK, AKT, PI3K, mTOR and RAS) are possible targets of new molecular treatment. A new paradigm of classification integrating the classic pathological criteria with the molecular changes will permit personalised prognosis and treatment.

the late 1990s, it was shown that GISTs share morphological, immunophenotypical and genetic characteristics with the interstitial cells of Cajal (ICCs), the pacemaker cells of the gut.^{2 12 13} They have immunophenotypical and ultrastructural features of both smooth muscle and neuronal differentiation, and regulate peristalsis. Most GISTs express the tyrosin kinase KIT oncoprotein^{2 14} that is also the immunohistochemical marker of ICC. The expression of KIT is so strong and specific that it was claimed to be required for the diagnosis,^{3–5 15 16} whereas it is now clear that a small, but significant fraction of GISTs (5–10%) are indeed KIT negative.^{17–20}

KIT is normally expressed in several cell types other than ICC.^{21 22} In particular, KIT expression has a crucial role in embryogenesis, encouraging differentiation of primitive mesenchymal progenitor cells towards ICC and is essential to the formation of a functional ICC network.¹² It belongs to the type III receptor tyrosine kinase (RTK) subfamily, whose members include platelet-derived growth factor receptors α and β (PDGFR α and PDGFR β). All RTKIII contain five immunoglobulin-like domains in their extracellular ligand-binding region followed by a single transmembrane domain and a cytoplasmic tyrosine kinase domain interrupted by a large kinase insert. The ligand of KIT is known as stem cell factor.²² As in other RTK, stem cell factor induces dimerisation of KIT followed by transautophosphorylation of the cytoplasmic tyrosine kinase domain, leading to activation of multiple signalling pathways, such as the PI3K/AKT and c-Jun N-terminal kinase/STAT pathways²³ (fig 1). The constitutive activation of KIT is one of the earliest transforming events in GISTs and occurs mainly through activating mutations in the *kit* gene,^{2 8 14 18 21 24–28} but there is evidence of alternate activating mechanisms in a subset of tumours. Activating mutations of *kit* gene in GIST occur in exons 11, 9, 13 and 17 (fig 1), corresponding to the juxtamembrane intracellular regulatory domain, the extramembrane domain and the two intracytoplasmic tyrosine kinase domains, respectively.^{18 29 30} In the first phase, the presence of activating mutations seemed to be related to a malignant behaviour.^{31 32} Subsequently, it was shown that most GISTs, even the tumours <1 cm in size that were found incidentally, do harbour KIT mutations.^{24 33–35} The meaning of KIT activation is highlighted by the recent introduction

Gastrointestinal stromal tumours (GIST), although relatively rare, are the most common primary mesenchymal tumours of the gastrointestinal tract, with an incidence of nearly 20/1 000 000/year.^{1–5} Their biological behaviour is difficult to predict, ranging from benign to malignant. The most reliable prognostic factors are size and mitotic index. On the basis of these factors (and to some extent on anatomical location), two risk classifications are proposed (tables 1 and 2).^{5 6}

Stromal tumours of the gastrointestinal tract were regarded as smooth-muscle tumours (leiomyoma, leiomyoblastoma) until electron microscopy and immunohistochemistry analysis showed that only a small fraction of these tumours showed smooth-muscle differentiation. Therefore, in 1983 Mazur and Clark⁹ proposed the non-committal designation, stromal tumour, which now encompasses tumours with schwannian or neuronal differentiation (gastrointestinal autonomic nerve tumours,¹⁰). We now know that GISTs may have either a well-developed or an incomplete myoid, neural, autonomic nerve or mixed phenotype, or may remain undifferentiated.^{5 11} In

See end of article for authors' affiliations

Correspondence to:
Dr Luigi Tornillo, Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003 Basel, Switzerland; tornillo@uhbs.ch

Accepted for publication
17 January 2006

Abbreviations: GIST, gastrointestinal stromal tumours; ICC, interstitial cells of Cajal; PDGFR, Platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3-kinase; RTK, receptor tyrosine kinases

Table 1 Risk assessment categories of gastrointestinal stromal tumours based on size and mitotic index

Risk category	Size (cm)	Mitoses (HPF)
Very low risk	<2	≤5/50
Low risk	2–5	≤5/50
Intermediate risk	≤5	5–10/50
	5–10	≤5/50
High risk	>5	>5/50
	>10	Any mitotic rate
	Any size	>10/50

HPF, high power field.
Data from Fletcher *et al.*⁵

of an inhibitor of RTKs, STI-571 (Imatinib, Gleevec, Novartis, Switzerland), which can induce regression of GISTs. Even advanced disease has been stabilised, with a return of quality of life.^{36–42} The proper application of STI-571 is currently being investigated to identify the patients most likely to benefit from the treatment. So far, it is indicated for the treatment of metastatic inoperable disease or for cytoreduction in cases not amenable to macroscopically complete resection.⁴³ Many trials are in course which are, however, considering the possibility of using the drug in an adjuvant or neoadjuvant setting.⁴⁴

Another member of the RTK family, PDGFR α , is associated with the pathogenesis of GIST and mutations in *c-kit* are mutually exclusive with those in *pdgfra*.⁴⁵ Interestingly, these two genes are located in the same chromosomal region (4q12).^{46–47} The most frequent mutations in *pdgfra* are observed in exons 18 (second tyrosine kinase domain), 12 (regulatory juxtamembrane domain) or 14 (tyrosine kinase domain) (fig. 1). Both in vitro⁴⁸ and in vivo⁴⁹ studies have shown that the type of mutation in *c-kit* or *pdgfra* genes may predict the response to treatment with imatinib. It is now well known that a mutation in exon 11 of *kit* is associated with a better response to treatment with inhibitors of RTK, with a decreasing response for mutation in exons 9, 13, 17 and wild-type tumours. Depending on the mutation, some cells expressing the PDGFR α exon 18 mutant were sensitive to imatinib, whereas others were resistant. Mutants in exons 14 and 12 are sensitive to the drug.^{14–49–50} Moreover, tumours with mutations in the *pdgfra* gene are prevalently epithelioid.⁵¹ Some specific RTK mutations are also correlated with clinicopathological parameters, such as histological type, overall survival, localisation and risk classification.^{48–49–52–53} Table 3 shows a brief summary of this correlation.

MUTATIONS OF THE KIT GENE

Exon 11 (juxtamembrane domain)

The juxtamembrane region of KIT inhibits receptor dimerisation in the absence of stem cell factor. Small in-frame deletions and insertions or point mutations on this domain affect this function.^{54–55} The reported frequency of mutations in exon 11 varies from 20% to 92%, depending on the type of material (frozen or formalin fixed) and the technique used.^{8–14–18–31–33–51–56–57} Most of the mutations are located between codons 556 and 560, with deletions and insertions prevalently affecting codons 557–559 and point mutations affecting codons 559 and 560.^{8–24–49–51–53–58–60} Internal tandem duplications are prevalently found towards the end of the exon (codons 576–580).⁵² The type of mutation is apparently related to the prognosis, with deletions behaving more aggressively in comparison with insertions and point mutations,^{8–18–29–58–61–63} and to the risk classification.

Exon 9 (extracellular domain)

The frequency of this mutation is described in 5–18% of cases, depending on the series.^{18–24–28–49–53–64–72} It occurs mainly at codons 501–502 and is represented by duplication–insertion.

Table 2 Risk assessment categories of gastrointestinal stromal tumours based on size, mitotic index and anatomical location

Group	Size (cm)	Mitoses (HPF)	Risk category
1	≤2	≤5/50	Stomach: benign Small intestine: benign
2	2–5	≤5/50	Stomach: very low malignant potential Small intestine: low malignant potential
3a	5–10	≤5/50	Stomach: very low malignant potential Small intestine: malignant potential
3b	>10	≤5/50	Stomach: low–moderate malignant potential Small intestine: malignant potential
4	≤2	>5/50	Stomach: uncertain Small intestine: malignant potential
5	2–5	>5/50	Stomach: low–moderate malignant potential Small intestine: malignant potential
6a	>5	>5/50	Stomach: malignant potential
6b	>10	>5/50	Small intestine: malignant potential

HPF, high power field.

Data from Miettinen *et al.*^{7–8}

Benign: no tumour-related mortality detected; very low malignant potential: <3% progressive disease; uncertain: insufficient data; low–moderate malignant potential: 12–15% tumour-related mortality; malignant potential: 49–86% tumour-related mortality.^{7–8}

It is associated with small intestinal localization and aggressive behaviour.^{18–24} Its mechanism probably affects an antidimerisation motif in the extracellular domain.

Exon 13 (kinase I domain)

This rare mutation, affecting codon 642, occurs in 0.8–4.1% of cases.^{1–3–35–49–64–66–70–71–73–74} It is associated with resistance to treatment with imatinib.

Exon 17 (activation loop)

The activating mechanism of these rare mutations (0.6% of cases)^{18–33} affecting codons 820 and 822, is unclear. A mutation occurring at codon 817, highly activating and frequently observed in other tumours (mastocytosis, acute myelogenous leukaemia), was never observed in GISTs, implying that the transforming mechanisms in the genesis of GIST are different from those of other tumours.^{18–23}

MUTATION IN THE PDGFRA GENE

They are observed in 7–12% of cases,^{18–20–29–45–49–50–51} occurring more often in exon 18 (activation loop) and rarely in exons 12 (juxtamembrane domain) and 14 (kinase I domain). *pdgfra* Mutants are prevalently epithelioid, located in the stomach and show weak or no immunohistochemical reactivity for KIT,^{18–20–29–45–49–51–75–76} but are functionally similar to *kit* mutants. The mutations occur in homologous domains, and activation of the downstream signalling pathways seem to be largely similar in the two mutant subtypes.⁷⁷ Some degree of difference in gene expression may exist, but these data need confirmation in larger series.⁷⁸

Exon 18 (activation loop)

Mutations occur at codons 842–849. Some of them (D842V, R841–842KI and D842–843IM) have shown considerable resistance to treatment with imatinib.^{45–48–49–79}

Exon 12 (juxtamembrane domain)

Mutations occur at codons 561–571 and are associated with good response to imatinib.^{18–48–50}

Figure 1 A simplified scheme of the signal transduction pathways activated by KIT or platelet-derived growth factor receptor α (PDGFR α) (PI3K/AKT, Ras/mitogen activated protein kinase, JAK/STAT, sarcoma inducing gene with indication of the sites of activating mutations described in gastrointestinal stromal tumours. Actual and future drug targets are shown in bold. RTK, receptor tyrosine kinase; Lig, ligand; JM, juxtamembrane regulatory domain; TK, tyrosine kinase domain.

Exon 14 (kinase I domain)

A single rare mutation is described (N659K). It showed in vitro sensitivity to imatinib that is comparable to that observed in *kit* exon 13 mutants.^{20 50}

GISTS IN THE PAEDIATRIC AGE GROUP

Most GISTs (95%) arise in adults over 40 years of age.^{80 81} Some GISTs in children (6–14 years) and young adults (15–24 years) occur in connection with Carney’s triad or neurofibromatosis type 1.^{82–84} Rare cases of familial GISTs are described, which carry a *kit* or *pdgfra* germline mutation.^{57 85–93}

Sporadic paediatric GISTs

Two series of paediatric GISTs^{6 72} showed that these tumours occur without mutations in both *kit* and *pdgfra*. They show

mainly an indolent course, with treatable recurrence. A specific gene expression signature was found in five cases, including overexpression of phosphate kinase alpha 1 (PHKA1), previously reported in a subset of acute myelogenous leukaemia in elderly women.⁷²

Paediatric GISTs associated with syndromes

GISTs associated with neurofibromatosis type 1 do not have mutations in the *kit* or *pdgfra* gene, except in rare cases, not corresponding to the hot spots of sporadic GISTs.^{82 94–96} They show an indolent course, preferential location in the small bowel and the colon and a tendency for multiple tumours.^{82 94–96}

Carney’s triad⁹⁷ is an association of GIST, paraganglioma and pulmonary chordoma. The genetic basis is unknown. In

Table 3 Summary of most frequent *kit* and *pdgfra* mutations in sporadic gastrointestinal stromal tumours

Gene	Exon	Frequency (%)	Mutation	Remarks
<i>kit</i>	11	20–60	Deletion–insertion 550–561 Point mutations 557, 559, 560, 576 Internal tandem duplications beyond 570 (3’ end)	Deletion is often associated with bad prognosis. Good response to imatinib
	9	10–15	Duplication–insertion 501–502	Malignant behaviour Small intestine Intermediate response to imatinib
	13	<5	Point mutation 642	Bad response to imatinib
	17	Rare (<1)	Point mutation 820	Bad response to imatinib
<i>pdgfra</i>	12	Roughly 1	Point mutation 561 Deletion–insertion 560–571 Insertion 582–586	Good response to imatinib
	14	<0.5	Point mutation 659	
	18	2–3	Point mutation 842 Deletion–substitution 842–847	Mutation 842 (D842V) resistant to imatinib Other sensitive

all, 85% of patients are women. The diagnosis is generally made at a young age or in infancy. GISTs associated with Carney's triad do not harbour mutations in the *kit* or *pdgfra* genes.^{18 98}

Familial GISTs are rare.^{57 85–93} Most affected families carry a *kit* germline mutation, inherited as autosomal dominant. One family showed a mutation in the *pdgfra* gene. Tumours are usually multiple and multifocal and arise at earlier ages than sporadic GISTs. They are associated with urticaria pigmentosa, melanocytic nevi, melanomas, achalasia or neuronal hyperplasia of the myenteric plexus.^{57 85–93} Genetic mechanisms of progression are similar in familial and sporadic GISTs in adults.⁹³

Cytogenetic changes in GISTs

The cytogenetic changes in GISTs were extensively studied by using different techniques (table 4).^{99–108}

A correlation between the number and type of chromosomal changes and biological behaviour of GISTs was suggested.²¹ Karyotypes from about 60% of GISTs show a partial or total loss of chromosome 14.^{21 45 104 109} In particular, 14q11.1–12 and 14q22–24 are frequently deleted and can therefore represent sites for tumour suppressor genes participating early in the genesis of GISTs.^{104 110} Loss of 22q is observed in about half of GISTs, with a higher frequency in advanced tumours.^{77 111} It is possible therefore that an unknown gene on 22q may be responsible in the early stages of tumorigenesis and in tumour progression.^{18 45 111} Intermediate-risk and high-risk GISTs show loss of chromosomes 1p, 9p, 9q, 11p^{100 102 104 106 108 111} and gains of 8q and 17q.^{100 102 105 108} A sort of molecular pathway in the acquisition of genetic aberrations may parallel the progressive acquisition of malignancy.¹⁸ The precise role of single changes and their prognostic impact was not elucidated. Probably, cytogenetic changes in GISTs, above all in those with intermediate- and high-risk, are more complex.^{35 53 61 77 112 113} For instance, 8q gains were described in as many as 57% of metastatic GISTs.¹⁰⁰ Gains of *c-myc*, a well-known oncogene located on 8q24.12–13, in only 3 of 100 GISTs,⁶¹ implies that the target of this amplification are other, still unknown, oncogenes.

Cell cycle network and GIST

One possible target on chromosome 9p is the cyclin-dependent kinase inhibitor 2A (*cdkn2a*) gene, located on 9p21, with its two transcripts, p16INK4a and p14ARF, which results from an alternative reading frame on the first exon.¹¹⁴ *cdkn2a* has a central role in the control of cell cycle and apoptosis. p14ARF inhibits mouse double minute 2 (MDM2) from degrading p53.¹¹⁵ p16INK4A binds to the cyclin-dependent kinase 4 and blocks the phosphorylation of RB1

protein, with consequent binding of the RB1 to E2F1, which may influence the expression of thousand genes responsible for the control of proliferation, transcription and apoptosis.^{116–118} Inactivation of p16INK4 may occur through mutation or promoter hypermethylation.^{116 117} Molecular genetics and immunohistochemistry showed^{113 119 120} that a loss of p16 may have an independent value in identifying a subset of tumours with adverse prognosis. These results are supported by the observation that dysregulation of other members of the CDKN2a network may be linked to adverse prognosis.¹¹⁶ We⁶¹ analysed a series of 100 GISTs by fluorescent in situ hybridisation (FISH) and found amplifications of CyclinD1 (*ccnd1*) and *mdm2* genes in a subset of high-risk tumours. Mouse double minute 2 interacts with Raf/methyl-ethyl ketone /mitogen activated protein kinase¹²¹ and phosphatidylinositol-3-kinase/AKT/c-Jun N-terminal kinase^{122 123} pathways, both of which are triggered by KIT-activation.^{18 21 124} We also found three cases of coamplifications of *ccnd1* and *mdm2*.^{61 125} An immunohistochemical study attempted to relate the cell cycle machinery and prognosis in 80 GISTs.¹²⁶ Cyclin A, cyclin B1, cdc2 and Ki-67 were associated with a high risk of malignant behaviour and short disease-free survival.

EXPRESSION STUDIES

The first study of gene expression in GISTs³⁴ showed that the presence of *kit* mutations (at that time, the presence of *pdgfra* mutations was not known) could identify a homogeneous expression profile, distinguishing GISTs from other mesenchymal tumours. In particular, genes that probably participated in the pacemaker function of the ICC (ion channels, receptors, transduction molecules) had a highly discriminant value. One of these protein kinase Cθ (*prkcθ*) is constitutively activated in GISTs and could therefore be a therapeutic target

Take-home messages

- Specific receptor tyrosine kinases (RTK) mutation is correlated with response-to-therapy and other clinico-pathological parameters.
- The prognostic impact of single cytogenetic alterations has not been elucidated.
- Factors different from RTK may regulate signalling in gastrointestinal stromal tumours.
- We need a new paradigm of classification that combines pathological criteria and molecular changes.

Table 4 Summary of cytogenetic changes in gastrointestinal stromal tumours

Changes	Method	Number of cases	Reference
–1p, –8p, –9, –10p, –10q, –13, –14q, –22q	FISH	14	Kim, 2000 ⁹⁹
–14q, –22q	FISH	12	Breiner <i>et al</i> ¹⁰⁶
–1p, –9p, –14q, –22q, +5p, +8q, +17q, +20q, –1, –7, –9, –13q14 (Rb1), –14q, –15, –22q, +3, +4, +8, +10	CGH	95	El-Rifai <i>et al</i> ¹⁰⁰
–1p, –13q, –14, –15, –22, +1q, +5, +17q, +20p	FISH	22	Debiec-Rychter <i>et al</i> ¹⁰⁴
–1p, –14, –21, –22, +7,	FISH	14	Derré <i>et al</i> ¹⁰⁵
–1p, –9p, –10q, –13q, –14, –15, –22, +5	Cytogenetics, spectral caryotyping	10	Andersson <i>et al</i> ³⁵
–1p, –9q, –14q, –15q, –22q, +4q, +5, +8q	Cytogenetics	19	Gunawan, 2002 ¹⁰⁷
	CGH	52	Gunawan <i>et al</i> ¹⁰⁸

CGH, comparative genomic hybridisation; FISH, fluorescent in situ hybridisation.

such as KIT.¹²⁷ Another marker that has been identified by gene expression analysis is DOG-1, and it has been proposed also as a possible diagnostic marker.¹²⁸ Subsequently gene expression in GISTs may differ according to the presence of mutation in *kit* or *pdgfra*,⁷⁷ to the type of mutations in *kit* or *pdgfra*^{78–129} or to the anatomical location of the tumour.¹²⁹ Differentially expressed genes included *e2rin*, *p70S6k*, *map2k1*, *akt*, *stat3*, all of which were in the activating pathways downstream of *kit* or *pdgfra*. Koon *et al*¹³⁰ described by real-time RT-PCR an association between the expression of cell cycle proteins (cyclinB1, centromere protein-F kinetochore protein) and tyrosine kinases with the biological behaviour in a small series of GISTs.

SIGNALLING PATHWAYS

KIT and PDGFR α in GISTs show a homogeneous transduction pathway consisting of mitogen-activate protein kinase, AKT, p70, STAT1, STAT3, PI3K, mammalian target of rapamycin and RAS.^{18–21–45} In particular, oncogenic signalling in these tumours differs from haematological diseases, and selective inhibition of the PI3K/mammalian target of rapamycin pathways reduces proliferation and inhibits apoptosis.^{25–26} The degree of activation differs from tumour to tumour, thus suggesting that factors different from KIT may regulate signalling in these neoplasias.²⁶ The development of new targeted molecular treatments is aimed at selectively blocking these pathways.

MOLECULAR CHANGES AND RESISTANCE TO IMATINIB

Many patients with advanced GISTs develop resistance after variable degrees of initial response to treatment.¹³¹ Two kinds of resistance should be distinguished:⁴⁴ (a) primary resistance: evidence of progression within the first 6 months of imatinib treatment, frequently associated with a wild-type KIT protein, mutation in exon 9 of *kit* or a D842V mutation in *pdgfra*; (b) secondary resistance: progression of disease after 6 months of treatment. The mechanisms of secondary resistance are heterogeneous: (a) acquisition of a secondary mutation in the *kit* or *pdgfra* genes;^{69–132–135} (b) genomic amplification of *kit* and overexpression of the protein;¹³³ and (c) activation of other RTKs.¹⁸ A new generation of tyrosine kinase inhibitors are presently under evaluation to solve this problem.^{132–136}

CONCLUSIONS

GISTs probably do not constitute a single group of tumours; their biological behaviour (the prognosis and above all the response to treatment) depends both on classic clinicopathological parameters (ie, location, size, mitotic activity) and on the molecular changes that are detected in a given tumour (type of mutation in RTK, chromosomal alterations, expression of cell cycle proteins, activation and control of pathways downstream of the RTK, amplification or loss of genes, etc). Moreover, a relationship was found between some pathological characteristics and molecular alterations (for instance, tumours of the small intestine are associated with epithelioid morphology and mutation in exon 9 of *kit*). This underlines the need for a new paradigm of classification that can combine the old pathological criteria with the molecular changes.¹⁸ In the era of targeted treatments (imatinib is one of the most successful examples), we are forced to change our point of view from the microscopic to the molecular level and to integrate all the data in a coherent schema.

Authors' affiliations

L Tornillo, L M Terracciano, Institute of Pathology, University of Basel, Basel, Switzerland

Competing interests: LT received a fee from Novartis for speaking. LT participated in 2004–5 in a study on gastrointestinal stromal tumours, which was funded by Novartis.

REFERENCES

- 1 Nilsson B, Bummig P, Meis-Kindblom JM, *et al*. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. *Cancer* 2005;**103**:821–9.
- 2 Kindblom LG, Remotti HE, Aldenborg F, *et al*. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. *Am J Pathol* 1998;**152**:1259–69.
- 3 Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. *Virchows Arch* 2001;**438**:1–12.
- 4 Miettinen M, El-Rifai W, Sobin HL, *et al*. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. *Hum Pathol* 2002;**33**:478–83.
- 5 Fletcher CD, Berman JJ, Corless C, *et al*. Diagnosis of gastrointestinal stromal tumors: a consensus approach. *Hum Pathol* 2002;**33**:459–65.
- 6 Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. *Am J Surg Pathol* 2005;**29**:1373–81.
- 7 Miettinen M, Kopczynski J, Makhlof HR, *et al*. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. *Am J Surg Pathol* 2003;**27**:625–41.
- 8 Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol* 2005;**29**:52–68.
- 9 Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. *Am J Surg Pathol* 1983;**7**:507–19.
- 10 Lauwers GY, Erlandson RA, Casper ES, *et al*. Gastrointestinal autonomic nerve tumors. A clinicopathological, immunohistochemical, and ultrastructural study of 12 cases. *Am J Surg Pathol* 1993;**17**:887–97.
- 11 Suster S. Gastrointestinal stromal tumors. *Semin Diagn Pathol* 1996;**13**:297–313.
- 12 Huizinga JD, Thuneberg L, Kluppel M, *et al*. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. *Nature* 1995;**373**:347–9.
- 13 Sircar K, Hewlett BR, Huizinga JD, *et al*. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. *Am J Surg Pathol* 1999;**23**:377–89.
- 14 Hirota S, Isozaki K, Moriyama Y, *et al*. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998;**279**:577–80.
- 15 Fletcher CD, Fletcher JA. Testing for KIT (CD117) in gastrointestinal stromal tumors: another Herceptest? *Appl Immunohistochem Mol Morphol* 2002;**10**:197–8.
- 16 Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. *Eur J Cancer* 2002;**38**(Suppl 5):S39–51.
- 17 Adachi Y, Yamamoto H, Noshio K, *et al*. Gigantic gastrointestinal stromal tumor in the pelvis. *Int J Colorectal Dis* 2005;**20**:196–8.
- 18 Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. *J Clin Oncol* 2004;**22**:3813–25.
- 19 Debiec-Rychter M, Wasag B, Stul M, *et al*. Gastrointestinal stromal tumors (GISTs) negative for KIT (CD117 antigen) immunoreactivity. *J Pathol* 2004;**202**:430–8.
- 20 Medeiros F, Corless CL, Duensing A, *et al*. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. *Am J Surg Pathol* 2004;**28**:889–94.
- 21 Heinrich MC, Rubin BP, Longley BJ, *et al*. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. *Hum Pathol* 2002;**33**:484–95.
- 22 Ashman LK. The biology of stem cell factor and its receptor C-kit. *Int J Biochem Cell Biol* 1999;**31**:1037–51.
- 23 Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. *Leuk Res* 2001;**25**:571–6.
- 24 Corless CL, McGreevey L, Haley A, *et al*. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. *Am J Pathol* 2002;**160**:1567–72.
- 25 Duensing A, Heinrich MC, Fletcher CD, *et al*. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. *Cancer Invest* 2004;**22**:106–16.
- 26 Duensing A, Medeiros F, McConarty B, *et al*. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). *Oncogene* 2004;**23**:3999–4006.
- 27 Hirota S, Isozaki K, Nishida T, *et al*. Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract. *J Gastroenterol* 2000;**35**(Suppl 12):75–9.
- 28 Hirota S, Nishida T, Isozaki K, *et al*. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors. *J Pathol* 2001;**193**:505–10.
- 29 Corless CL. Assessing the prognosis of gastrointestinal stromal tumors: a growing role for molecular testing. *Am J Clin Pathol* 2004;**122**:11–3.

- 30 Sihto H, Sarlomo-Rikala M, Tynnen O, *et al*. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. *J Clin Oncol* 2005;**23**:49–57.
- 31 Lasota J, Jasinski M, Sarlomo-Rikala M, *et al*. Mutations in exon 11 of c-KIT occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. *Am J Pathol* 1999;**154**:53–60.
- 32 Taniguchi M, Nishida T, Hirota S, *et al*. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. *Cancer Res* 1999;**59**:4297–300.
- 33 Rubin BP, Singer S, Tsao C, *et al*. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. *Cancer Res* 2001;**61**:8118–21.
- 34 Allander SV, Nupponen NN, Ringner M, *et al*. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. *Cancer Res* 2001;**61**:8624–8.
- 35 Andersson J, Sjogren H, Meis-Kindblom JM, *et al*. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. *Am J Pathol* 2002;**160**:15–22.
- 36 Tuveson DA, Willis NA, Jacks T, *et al*. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. *Oncogene* 2001;**20**:5054–8.
- 37 Levitzki A. Tyrosine kinases as targets for cancer therapy. *Eur J Cancer* 2002;**38**(Suppl 5):S11–8.
- 38 Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Gleevec). *Med Klin* 2002;**97**(Suppl 1):28–30.
- 39 Joensuu H, Roberts PJ, Sarlomo-Rikala M, *et al*. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *N Engl J Med* 2001;**344**:1052–6.
- 40 Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. *Semin Oncol* 2001;**28**(5 Suppl 17):19–26.
- 41 Demetri GD. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. *Hematol Oncol Clin North Am* 2002;**16**:1115–24.
- 42 Demetri GD, von Mehren M, Blanke CD, *et al*. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;**347**:472–80.
- 43 Dagher R, Cohen M, Williams G, *et al*. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. *Clin Cancer Res* 2002;**8**:3034–8.
- 44 Blay JY, Bonvalot S, Casali P, *et al*. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. *Ann Oncol* 2005;**16**:566–78.
- 45 Heinrich MC, Corless CL, Duensing A, *et al*. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;**299**:708–10.
- 46 Hsieh CL, Navankasattus S, Escobedo JA, *et al*. Chromosomal localization of the gene for AA-type platelet-derived growth factor receptor (PDGFRA) in humans and mice. *Cytogenet Cell Genet* 1991;**56**:160–3.
- 47 d'Auriol L, Mattei MG, Andre C, *et al*. Localization of the human c-kit protooncogene on the q11–q12 region of chromosome 4. *Hum Genet* 1988;**78**:374–6.
- 48 Hirota S, Ohashi A, Nishida T, *et al*. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. *Gastroenterology* 2003;**125**:660–7.
- 49 Heinrich MC, Corless CL, Demetri GD, *et al*. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* 2003;**21**:4342–9.
- 50 Corless CL, Schroeder A, Griffith D, *et al*. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol* 2005;**23**:5357–64.
- 51 Lasota J, Dansonka-Mieszkowska A, Sobin LH, *et al*. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. *Lab Invest* 2004;**84**:874–83.
- 52 Lasota J, Dansonka-Mieszkowska A, Stachura T, *et al*. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. *Mod Pathol* 2003;**16**:1257–64.
- 53 Lasota J, Kopczynski J, Sarlomo-Rikala M, *et al*. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal s of intestinal origin. *Hum Pathol* 2003;**34**:1306–12.
- 54 Chan PM, Ilangumaran S, La Rose J, *et al*. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. *Mol Cell Biol* 2003;**23**:3067–78.
- 55 Kitayama H, Kanakura Y, Furitsu T, *et al*. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. *Blood* 1995;**85**:790–8.
- 56 Ernst SI, Hubbs AE, Przygodzki RM, *et al*. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. *Lab Invest* 1998;**78**:1633–6.
- 57 Li SQ, O'Leary TJ, Sobin LH, *et al*. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. *Acta Cytol* 2000;**44**:981–6.
- 58 Corless CL, McGreevey L, Town A, *et al*. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. *J Mol Diagn* 2004;**6**:366–70.
- 59 Miettinen M, Furlong M, Sarlomo-Rikala M, *et al*. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. *Am J Surg Pathol* 2001;**25**:1121–33.
- 60 Miettinen M, Sobin LH. Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases. *Am J Surg Pathol* 2001;**25**:1433–7.
- 61 Tornillo L, Duchini G, Carafa V, *et al*. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). *Lab Invest* 2005;**85**:921–31.
- 62 Wardelmann E, Losen I, Hans V, *et al*. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. *Int J Cancer* 2003;**106**:887–95.
- 63 Martin J, Poveda A, Llombart-Bosch A, *et al*. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). *J Clin Oncol* 2005;**23**:6190–8.
- 64 Sakurai S, Oguni S, Hironaka M, *et al*. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. *Jpn J Cancer Res* 2001;**92**:494–8.
- 65 Lux ML, Rubin BP, Biase TL, *et al*. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. *Am J Pathol* 2000;**156**:791–5.
- 66 Debiec-Rychter M, Dumez H, Judson I, *et al*. Use of c-KIT/PDGFRα mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2004;**40**:689–95.
- 67 Kim TW, Lee H, Kang YK, *et al*. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. *Clin Cancer Res* 2004;**10**:3076–81.
- 68 Yamamoto H, Oda Y, Kawaguchi K, *et al*. c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). *Am J Surg Pathol* 2004;**28**:479–88.
- 69 Chen LL, Trent JC, Wu EF, *et al*. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. *Cancer Res* 2004;**64**:5913–9.
- 70 Willmore C, Holden JA, Zhou L, *et al*. Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. *Am J Clin Pathol* 2004;**122**:206–16.
- 71 Antonescu CR, Sommer G, Sarrao L, *et al*. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. *Clin Cancer Res* 2003;**9**:3329–37.
- 72 Prakash S, Sarrao L, Sacci N, *et al*. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. *J Pediatr Hematol Oncol* 2005;**27**:179–87.
- 73 Kinoshita K, Isozaki K, Hirota S, *et al*. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. *J Gastroenterol Hepatol* 2003;**18**:147–51.
- 74 Joensuu H, Kindblom LG. Gastrointestinal stromal tumors—a review. *Acta Orthop Scand Suppl* 2004;**75**:62–71.
- 75 Pauls K, Merkelbach-Bruse S, Thal D, *et al*. PDGFRAα- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. *Histopathology* 2005;**46**:166–75.
- 76 Penzel R, Aulmann S, Moock M, *et al*. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. *J Clin Pathol* 2005;**58**:634–9.
- 77 Subramanian S, West RB, Corless CL, *et al*. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. *Oncogene* 2004;**23**:7780–90.
- 78 Kang HJ, Nam SW, Kim H, *et al*. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. *Oncogene* 2005;**24**:1066–74.
- 79 Ohashi A, Kinoshita K, Isozaki K, *et al*. Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-α. *Int J Cancer* 2004;**111**:317–21.
- 80 DeMatteo RP, Lewis JJ, Leung D, *et al*. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 2000;**231**:51–8.
- 81 Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. *Am J Gastroenterol* 2005;**100**:162–8.
- 82 Andersson J, Sihto H, Meis-Kindblom JM, *et al*. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. *Am J Surg Pathol* 2005;**29**:1170–6.
- 83 Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. *Am J Med Genet* 2002;**108**:132–9.
- 84 Kinoshita K, Hirota S, Isozaki K, *et al*. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. *J Pathol* 2004;**202**:80–5.
- 85 Beghini A, Tibiletti MG, Roversi G, *et al*. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. *Cancer* 2001;**92**:657–62.
- 86 Chen H, Hirota S, Isozaki K, *et al*. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. *Gut* 2002;**51**:793–6.
- 87 Chompret A, Kannengiesser C, Barrois M, *et al*. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. *Gastroenterology* 2004;**126**:318–21.

- 88 Hirota S, Nishida T, Isozaki K, *et al.* Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. *Gastroenterology* 2002;**122**:1493–9.
- 89 Hirota S, Okazaki T, Kitamura Y, *et al.* Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. *Am J Surg Pathol* 2000;**24**:326–7.
- 90 Maeyama H, Hidaka E, Ota H, *et al.* Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. *Gastroenterology* 2001;**120**:210–5.
- 91 Nishida T, Hirota S, Taniguchi M, *et al.* Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. *Nat Genet* 1998;**19**:323–4.
- 92 Hartmann K, Wardelmann E, Ma Y, *et al.* Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. *Gastroenterology* 2005;**129**:1042–6.
- 93 Li FP, Fletcher JA, Heinrich MC, *et al.* Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. *J Clin Oncol* 2005;**23**:2735–43.
- 94 Cheng SP, Huang MJ, Yang TL, *et al.* Neurofibromatosis with gastrointestinal stromal tumors: insights into the association. *Dig Dis Sci* 2004;**49**:1165–9.
- 95 Takazawa Y, Sakurai S, Sakuma Y, *et al.* Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). *Am J Surg Pathol* 2005;**29**:755–63.
- 96 Yantiss RK, Rosenberg AE, Sarran L, *et al.* Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. *Mod Pathol* 2005;**18**:47–84.
- 97 Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. *Mayo Clin Proc* 1999;**74**:543–52.
- 98 Diment J, Tamborini E, Casali P, *et al.* Carney triad: case report and molecular analysis of gastric tumor. *Hum Pathol* 2005;**36**:112–6.
- 99 Kim NG, Kim JJ, Aha JY, *et al.* Putative chromosomal deletions on 9p, 9q and 22q occur preferentially in malignant gastrointestinal stromal tumors. *Int J Cancer* 2000;**85**:633–8.
- 100 El-Rifai W, Sarlomo-Rikala M, Andersson LC, *et al.* DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. *Cancer Res* 2000;**60**:3899–03.
- 101 Sarlomo-Rikala M, El-Rifai W, Lahtinen T, *et al.* Different patterns of DNA copy number changes in gastrointestinal stromal tumors, leiomyomas, and schwannomas. *Hum Pathol* 1998;**29**:476–81.
- 102 Debiec-Rychter M, Pauwels P, Lasota J, *et al.* Complex genetic alterations in gastrointestinal stromal tumors with autonomic nerve differentiation. *Mod Pathol* 2002;**15**:692–8.
- 103 Debiec-Rychter M, Sciort R, Pauwels P, *et al.* Molecular cytogenetic definition of three distinct chromosome arm 14q deletion intervals in gastrointestinal stromal tumors. *Genes Chromosomes Cancer* 2001;**32**:26–32.
- 104 Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, *et al.* Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. *Cancer Genet Cytogenet* 2001;**128**:24–30.
- 105 Derre J, Lagace R, Terrier P, *et al.* Consistent DNA losses on the short arm of chromosome 1 in a series of malignant gastrointestinal stromal tumors. *Cancer Genet Cytogenet* 2001;**127**:30–3.
- 106 Breiner JA, Meis-Kindblom J, Kindblom LG, *et al.* Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). *Cancer Genet Cytogenet* 2000;**120**:111–6.
- 107 Gunawan B, Bergmann F, Hoer J, *et al.* Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. *Hum Pathol* 2002;**33**:316–21.
- 108 Gurchan B, Schulten HJ, von Heydebreck A, *et al.* Site-independent prognostic value of chromosome 9q loss in primary gastrointestinal stromal tumors. *J Pathol* 2004;**2002**:421–9.
- 109 Fukasawa T, Chong JM, Sakurai S, *et al.* Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. *Jpn J Cancer Res* 2000;**91**:1241–9.
- 110 El-Rifai W, Sarlomo-Rikala M, Andersson LC, *et al.* High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci. *Genes Chromosomes Cancer* 2000;**27**:387–91.
- 111 Lasota J, Wozniak A, Kopczynski J, *et al.* Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. *Lab Invest* 2005;**85**:237–47.
- 112 Lasota J, Wozniak A, Kopczynski J, *et al.* Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. *Lab Invest* 2005;**85**:237–47.
- 113 Schneider-Stock R, Boltze C, Lasota J, *et al.* Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. *Clin Cancer Res* 2005;**11**(2 Pt 1):638–45.
- 114 Quelle DE, Zindy F, Ashmun RA, *et al.* Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell* 1995;**83**:993–1000.
- 115 Pomerantz J, Schreiber-Agus N, Liegeois NJ, *et al.* The ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell* 1998;**92**:713–23.
- 116 Haller F, Gunawan B, von Heydebreck A, *et al.* Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. *Clin Cancer Res* 2005;**11**:6589–97.
- 117 Müller H, Bracken AP, Vernell R, *et al.* E2Fs regulate the expression of genes involved in differentiation, development, proliferation and apoptosis. *Genes Dev* 2001;**15**:267–85.
- 118 Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin/CDK4. *Nature* 1993;**366**:704–7.
- 119 Ricci R, Arena V, Castri F, *et al.* Role of p16/INK4a in gastrointestinal stromal tumor progression. *Am J Clin Pathol* 2004;**122**:35–43.
- 120 Schneider-Stock R, Boltze C, Lasota J, *et al.* High prognostic value of p16ink4 alterations in gastrointestinal stromal tumors. *J Clin Oncol* 2003;**21**:1688–97.
- 121 Ries S, Biederer C, Woods D, *et al.* Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. *Cell* 2000;**103**:321–30.
- 122 Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. *Proc Natl Acad Sci USA* 2001;**98**:11598–603.
- 123 Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. *Trends Biochem Sci* 2002;**27**:462–7.
- 124 Linnek D. Early signaling pathways activated by c-Kit in hematopoietic cells. *Int J Biochem Cell Biol* 1999;**31**:1053–74.
- 125 Xiao ZX, Chen J, Levine AJ, *et al.* Interaction between the retinoblastoma protein and the oncoprotein MDM2. *Nature* 1995;**375**:694–8.
- 126 Nakamura N, Yamamoto H, Yao T, *et al.* Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. *Hum Pathol* 2005;**36**:828–37.
- 127 Duensing A, Joseph NE, Medeiros F, *et al.* Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). *Cancer Res* 2004;**64**:5127–31.
- 128 West RB, Corless CL, Chen X, *et al.* The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. *Am J Pathol* 2004;**165**:107–13.
- 129 Antonescu CR, Viale A, Sarran L, *et al.* Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. *Clin Cancer Res* 2004;**10**:3282–90.
- 130 Koon N, Zaika A, Moskaluk CA, *et al.* Clustering of molecular alterations in gastroesophageal carcinomas. *Neoplasia* 2004;**6**:143–9.
- 131 Verweij J, Casali PG, Zalcberg J, *et al.* Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. *Lancet* 2004;**364**:1127–34.
- 132 Antonescu CR, Besmer P, Guo T, *et al.* Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. *Clin Cancer Res* 2005;**11**:4182–90.
- 133 Debiec-Rychter M, Cools J, Dumez H, *et al.* Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. *Gastroenterology* 2005;**128**:270–9.
- 134 Tamborini E, Bonadiman L, Greco A, *et al.* A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. *Gastroenterology* 2004;**127**:294–9.
- 135 Tamborini E, Gabanti E, Lagonigro MS, *et al.* KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient. *Cancer Res* 2005;**65**:1115; author reply 1115.
- 136 Growney JD, Clark JJ, Adelsperger J, *et al.* Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. *Blood* 2005;**106**:721–4.